Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome

Area of Science:

• Neuroscience
• Pharmacology
• Sleep Medicine

Background:

• Restless Legs Syndrome (RLS) is a neurological disorder characterized by an irresistible urge to move the legs.
• Periodic Leg Movements during Sleep (PLMS) are a common feature of RLS, significantly impacting sleep quality.
• Dopamine receptor agonists are a primary treatment for RLS, but the specific receptor subtype's role is debated.

Purpose of the Study:

• To compare the efficacy of a D3 preferential agonist (pramipexole) versus a D2 preferential agonist (bromocriptine) in treating RLS and PLMS.
• To determine which dopamine receptor subtype is more critical for alleviating RLS symptoms and PLMS.

Main Methods:

• A placebo-controlled, prospective, single-blind study involving 45 drug-naive idiopathic RLS patients.
• Two consecutive nights of polysomnography: one baseline, one with a single oral dose of pramipexole (0.25 mg), bromocriptine (2.5 mg), or placebo.
• Assessment of subjective restlessness symptoms and objective sleep parameters.

Main Results:

• Both pramipexole and bromocriptine improved subjective RLS symptoms, with pramipexole showing a greater effect.
• Pramipexole significantly improved sleep efficiency and reduced wakefulness after sleep onset compared to bromocriptine.
• Pramipexole was more effective in reducing PLMS, particularly in patients with high baseline PLMS index; typical PLMS disappeared completely after pramipexole.

Conclusions:

• Dopamine D3 receptor agonists, such as pramipexole, demonstrate superior efficacy in managing PLMS and RLS compared to D2 receptor agonists like bromocriptine.
• Targeting the D3 receptor subtype offers greater therapeutic benefits for RLS and PLMS.